49380 Federal Register / Vol. 74, No. 186 / Monday, September 28, 2009 / Notices 

cgi?P1_Prod_Version=ShockwaveFlash. 

Installation questions or troubleshooting 

help can be found at the same link. For 

optimal viewing, a high speed Internet 

connection is recommended. The 

Community Banking Advisory 

Committee meeting videos are made 

available on-demand approximately two 

weeks after the event. 

Dated: September 23, 2009. 

Robert E. Feldman, 

Committee Management Officer, 

Federal Deposit Insurance Corporation. 

[FR Doc. E9–23298 Filed 9–25–09; 8:45 am] 

BILLING CODE 6714–01–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisition of Shares of Bank or Bank 

Holding Companies 

The notificants listed below have 

applied under the Change in Bank 

Control Act (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire a bank or bank 

holding company. The factors that are 

considered in acting on the notices are 

set forth in paragraph 7 of the Act (12 

U.S.C. 1817(j)(7)). 

The notices are available for 

immediate inspection at the Federal 

Reserve Bank indicated. The notices 

also will be available for inspection at 

the office of the Board of Governors. 

Interested persons may express their 

views in writing to the Reserve Bank 

indicated for that notice or to the offices 

of the Board of Governors. Comments 

must be received not later than October 

13, 2009. 

A. Federal Reserve Bank of San 

Francisco (Kenneth Binning, Vice 

President, Applications and 

Enforcement) 101 Market Street, San 

Francisco, California 94105–1579: 

1. Alma Medina Vivar, Daly City, 

California; as part of a group acting in 

concert including Rommel and Ruell 

Medina, to individually acquire, and to 

collectively acquire, voting shares of 

MNB Holdings, Inc., and thereby 

indirectly acquire voting shares of 

Mission National Bank, both of San 

Francisco, California. 

Board of Governors of the Federal Reserve 

System, September 23, 2009. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E9–23356 Filed 9–25–09; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR Part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The applications also will be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Additional information on all bank 

holding companies may be obtained 

from the National Information Center 

website at www.ffiec.gov/nic/. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than October 23, 

2009. 

A. Federal Reserve Bank of 

Richmond (A. Linwood Gill, III, Vice 

President) 701 East Byrd Street, 

Richmond, Virginia 23261–4528: 

1. Nantahala Bancshares, Inc., 

Franklin, North Carolina; to become a 

bank holding company by acquiring 100 

percent of the voting shares of 

Nantahala Bank & Trust Company, 

Franklin, North Carolina. 

Board of Governors of the Federal Reserve 

System, September 23, 2009. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E9–23357 Filed 9–25–09; 8:45 am] 

BILLING CODE 6210–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30 Day–09–09CC] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

CDC American Recovery and 

Reinvestment Act of 2009 (ARRA) 

Performance Progress Report—New— 

Office of the Chief Operating Officer 

(OCOO), Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

The American Recovery and 

Reinvestment Act of 2009 was signed 

into law on February 17, 2009, Public 

Law 111–5 (‘‘Recovery Act’’). The 

purpose of this proposed data collection 

is to collect quarterly performance 

information for all CDC grants and 

cooperative agreements funded under 

the Recovery Act. This will allow CDC 

to receive reports on recipient 

performance measures as set forth in the 

applicable Funding Opportunity 

Announcement (FOA) and Notice of 

Grant Award. This requirement is in 

addition to the reporting requirements 

of Section 1512 of the Recovery Act, set 

forth by the Office of Management and 

Budget (OMB) under the data collection 

instrument titled ‘‘Standard Data 

Elements for Reports under Section 

1512 of the American Recovery and 

Reinvestment Act of 2009, Public Law 

111–5 (Grants, Cooperative Agreements 

and Loans).’’ 

The form CDC proposes to use is a 

modified Performance Progress Report 

(SF–PPR) which was successfully 

piloted by the Administration for 

Children and Families (ACF). CDC 

intends to use this modified form for 

quarterly standard reporting of 

performance measures set forth in the 

applicable FOA and Notice of Grant 

Award for all CDC Recovery Act funded 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 74, No. 186 / Monday, September 28, 2009 / Notices 49381 

grants and cooperative agreements. In 

addition to allowing for uniformity of 

information collection, this format will 

support systematic electronic collection 

and submission of information. The 

form contains non-personal identifying 

data elements and a section for a 

performance narrative. 

There are no costs to respondents 

other than their time. The total 

estimated annual burden hours are 

11,676. This estimate reflects an 

increase from the 60 day notice as a 

result of an increase in respondents and 

adjustments to average burden hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents 

Number of 

respondents 

(estimated) 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

States: Section 317 Immunization Program—Reaching More Children & 

Adults ........................................................................................................... 64 4 6 1,536 

States: Section 317 Immunization Program—Innovative Initiatives ................ 15 4 6 360 

States: Section 317 Immunization Program—Communication & Provider 

Education ..................................................................................................... 10 4 6 240 

States: Section 317 Immunization Program—Strengthening the Evidence 

Base ............................................................................................................. 64 4 6 1,536 

States: Healthcare Associated Infections—Emerging Infections Program ..... 10 4 6 240 

States: Healthcare Associated Infections—Epidemiology & Laboratory Capacity ............................................................................................................ 52 4 6 1,248 

States: Health Information Technology and Public Health .............................. 64 4 6 1,536 

Universities: Health Information Technology Professionals in Health Care .... 30 4 6 720 

States: Communities Putting Prevention to Work—Quitline Support .............. 50 4 2 400 

States: Communities Putting Prevention to Work—Policy Activities ............... 50 4 2 400 

States: Communities Putting Prevention to Work—Policy Implementation .... 50 2 1 100 

States: Communities Putting Prevention to Work—Community Policy Activities ................................................................................................................ 40 4 16 2,560 

Communities: Communities Putting Prevention to Work—Policy Implementation ............................................................................................................. 40 2 8 640 

State Cancer Registries: Comparative Effectiveness Research to Enhance 

Cancer Registry Data Systems .................................................................... 15 4 2 120 

Universities: Comparative Effectiveness Research to Improve Prevention 

and Wellness ................................................................................................ 5 4 2 40 

Dated: September 21, 2009. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E9–23311 Filed 9–25–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30 Day–09–07AA] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call Maryam I. Daneshvar, the 

CDC Reports Clearance Officer, at (404) 

639–5960 or send an e-mail to 

omb@cdc.gov. Send written comments 

to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Evaluating the Quality of Interview 

Data Collected by Teratology 

Information Services About Pregnancy 

Outcomes, Maternal and Infant Health, 

Following Medication Use During 

Pregnancy and Lactation—New— 

National Center on Birth Defects and 

Developmental Disabilities (NCBDDD), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

This data collection is based on the 

following components of the Public 

Health Service Act: (1) Act 42 USC 241, 

Section 301, which authorizes 

‘‘research, investigations, experiments, 

demonstrations, and studies relating to 

the causes, diagnosis, treatment, control, 

and prevention of physical and mental 

diseases and impairments of man.’’ (2) 

42 USC 247b–4, Section 317 C, which 

authorizes the activities of the National 

Center on Birth Defects and 

Developmental Disabilities. This section 

was created by Public Law 106–310, 

also known as ‘‘the Children’s Health 

Act of 2000.’’ This portion of the code 

has also been amended by Public Law 

108–154, which is also known as the 

‘‘Birth Defects and Developmental 

Disabilities Prevention Act of 2003’’. 

The use of a number of medications 

during pregnancy is known to be 

associated with serious adverse effects 

in children. However, because pregnant 

and lactating women are traditionally 

excluded from clinical trials, and 

because premarketing animal studies do 

not necessarily predict the experience of 

humans, little information is available 

about the safety of most prescription 

medications during pregnancy and 

lactation at the time they are marketed. 

Nevertheless, many women 

inadvertently use medications early in 

gestation before realizing they are 

pregnant, and many maternal conditions 

require treatment during pregnancy and 

breastfeeding to safeguard the health of 

both mother and infant. Currently, the 

United States does not does not conduct 

comprehensive monitoring for 

pregnancy or infant outcomes related to 

medication exposures. To try to address 

these concerns, a number of 

pharmaceutical manufacturers have 

established pregnancy drug registries to 

monitor the effects of use of selected 

medications during pregnancy on 

pregnancy outcomes and fetal and 

infant health. In some instances, the 

U.S. Food and Drug Administration has 

required postmarketing monitoring of 

pregnancy outcomes after medication 


srobinson on DSKHWCL6B1PROD with NOTICES